Annunziata Carbonara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annunziata Carbonara has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Alsadig
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany
1 shared publication - Alessia Foscarini
CNR NANOTEC Institute of Nanotechnology, via Monteroni, 73100 Lecce, Italy
1 shared publication - Antonio Turco
CNR NANOTEC Institute of Nanotechnology, via Monteroni, 73100 Lecce, Italy
1 shared publication - Benedetta Stampone
Department of Mathematics & Physics E. de Giorgi, University of Salento, Via Arnesano, 73100 Lecce, Italy
1 shared publication - Elisabetta Primiceri
CNR Nanotec – Institute of Nanotechnology Lecce Italy
1 shared publication - Francesco Ferrara
CNR NANOTEC Institute of Nanotechnology, via Monteroni, 73100 Lecce, Italy
1 shared publication
Latest Publications
- Open Access
- 10 May 2024
- Published by MDPI AG in Proceedings
- Vol. 97 (1) , 214
TITAN Project: Microfluidic and Sensing Tools for Immunotherapy
The TITAN project aims to improve immunotherapy, targeting the efficiency of methods to obtain genetically engineered T cells. Immunotherapy has achieved great success in clinical trials, but it is currently very expensive in terms of time required for analysis, reagents, and samples. TITAN aims to the continuous sampling of critical quality attributes, in order to quickly recognize deviations from the desired range and take appropriate corrective actions on process parameters for an optimal outcome. To achieve its aims, TITAN is currently developing microfluidic and sensing tools for the accurate and efficient real-time monitoring of the T cells amplification process.
- 10 May 2024
- Published by MDPI AG in Proceedings
- Vol. 97 (1) , 214
Open AccessTITAN Project: Microfluidic and Sensing Tools for Immunotherapy
The TITAN project aims to improve immunotherapy, targeting the efficiency of methods to obtain genetically engineered T cells. Immunotherapy has achieved great success in clinical trials, but it is currently very expensive in terms of time required for analysis, reagents, and samples. TITAN aims to the continuous sampling of critical quality attributes, in order to quickly recognize deviations from the desired range and take appropriate corrective actions on process parameters for an optimal outcome. To achieve its aims, TITAN is currently developing microfluidic and sensing tools for the accurate and efficient real-time monitoring of the T cells amplification process.